Skip to main content

Table 2 Measurements of cardiac function by echocardiography

From: I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice

 

Ivabradine (n = 7)

Control(n = 6)

P value

IVSTd (mm)

   

  Baseline

0.95 ± 0.12

0.89 ± 0.18

0.539

  At 3 months

1.09 ± 0.12

0.94 ± 0.15

0.089

IVSTs (mm)

   

  Baseline

1.37 ± 0.17

1.29 ± 0.21

0.468

  At 3-month

1.59 ± 0.03

1.24 ± 0.21

0.022

LVDd (mm)

   

  Baseline

3.30 ± 0.31

3.33 ± 0.27

0.932

  At 3-month

2.99 ± 0.14

3.24 ± 0.25

0.497

LVDs (mm)

   

  Baseline

2.09 ± 0.17

2.26 ± 0.50

0.436

  At 3-month

1.65 ± 0.08

2.22 ± 0.53

0.017

LVPWd (mm)

   

  Baseline

0.92 ± 0.18

0.84 ± 0.12

0.353

  At 3-month

1.09 ± 0.09

0.94 ± 0.16

0.067

LVPWs (mm)

   

  Baseline

1.21 ± 0.09

1.18 ± 0.11

0.577

  At 3-month

1.42 ± 0.09

1.26 ± 0.14

0.032

EF (%)

   

  Baseline

67.1 ± 6.96

61.6 ± 7.6

0.202

  At 3-month

75.7 ± 3.43

54.1 ± 8.3

0.018

FS (%)

   

  Baseline

36.42 ± 5.56

31.66 ± 4.96

0.135

  At 3-month

49.33 ± 3.01

27.34 ± 4.87

<0.001

LVM (g)

   

  Baseline

107.55 ± 10.75

99.81 ± 15.88

0.596

  At 3-month

85.85 ± 13.04

98.39 ± 27.92

0.309

LVM-corrected(mm)

   

  Baseline

86.04 ± 8.59

79.99 ± 28.77

0.605

  At 3-month

66.65 ± 10.51

78.60 ± 22.30

0.230

LVDd (ml)

   

  Baseline

44.84 ± 10.25

51.99 ± 25.65

0.509

  At 3-month

48.07 ± 6.69

49.32 ± 28.40

0.911

LVSd (ml)

   

  Baseline

14.42 ± 2.67

19.79 ± 10.24

0.206

  At 3-month

11.97 ± 2.02

19.82 ± 11.06

0.091

  1. IVST, inter-ventricular septal thickness; d, end-diastolic; s, end-systolic; LVD, left ventricular dimension; LVPW, left ventricular posterior wall; EF, eject fraction; FS, fraction of shortness; LVM, left ventricular mass.